CYP3A4

CYP3A4 is the most abundant cytochrome P450 enzyme in the human liver and the lining of the small intestine. Cytochrome P450 enzymes are a family of oxidative proteins whose primary job is to chemically alter foreign molecules — drugs, plant compounds, hormones — so the body can excrete them.

CYP3A4 is estimated to handle the metabolism of a large proportion of all clinically used drugs, making it one of the most consequential proteins in pharmacology. Its activity varies considerably between individuals, which is one reason two people can respond very differently to the same dose of a substance.

How it works · its role

CYP3A4 works by adding oxygen atoms to its substrates — the drug molecules it acts on — converting lipid-soluble compounds into more water-soluble forms that can be filtered by the kidneys and excreted. This process, called phase I metabolism, usually deactivates a drug, though in some cases it converts an inactive prodrug into its active form.

Other substances can alter how fast CYP3A4 works. Inducers increase its activity, speeding up the breakdown of anything it metabolises and lowering plasma levels of co-administered drugs. Inhibitors slow it down, causing drug concentrations to rise higher and last longer than expected.

Grapefruit juice is a well-known inhibitor — it contains compounds that block the enzyme in the gut wall, raising blood levels of many drugs substantially.

Relevance to substances & effects

A wide range of psychoactive substance classes are CYP3A4 substrates. Benzodiazepines are among the most clinically significant: most are metabolised substantially through this pathway, so any inhibitor taken alongside them can produce unexpectedly deep sedation.

Many opioids — including fentanyl and oxycodone — are also CYP3A4 substrates, and their effects can be amplified or shortened depending on what else is in the system. Cannabinoids, including THC and CBD, interact with the enzyme in both directions: CBD in particular is a meaningful inhibitor at typical doses.

Some antidepressants act as inhibitors, and certain anticonvulsants and St John's Wort are strong inducers — a clinically relevant consideration when either is combined with a CYP3A4-metabolised psychoactive. The practical consequence is that the same nominal dose of a substance can produce very different effects depending on a person's CYP3A4 activity and what else they have taken.

Clinical · risk note

The main risk from CYP3A4 interactions is dose unpredictability. When the enzyme is inhibited, a drug that would ordinarily be cleared quickly accumulates — pushing concentrations into ranges that can cause respiratory depression with sedatives or opioids, or cardiac effects with other compounds.

Induction carries the opposite hazard: a drug that normally works reliably may be metabolised so quickly that it becomes ineffective, or — if it is a prodrug — converted to its active form faster and in larger amounts than expected.

Because the enzyme handles so many different substances simultaneously, the interactions can be difficult to predict in polydrug contexts. This is one reason that combining depressants, or adding an herbal preparation to a prescription drug, carries more uncertainty than the individual substances might suggest.